 |
7 Diseases |  |
0 Trials |
|
0 Trials |  |
30 News |  |
- | Lisofylline / Islet Sci
Retrospective data, Journal: High Levels of Triggering Receptor Expressed in Myeloid Cells-Like Transcript-1 Positive, but Not Glycoprotein 1b+, Microparticles Are Associated With Poor Outcomes in Acute Respiratory Distress Syndrome. (Pubmed Central) - Jun 27, 2024
Although both ?IIb?IIIa+ and TLT+ microparticles (?IIb?IIIa, TLT-1) were associated with mortality, TLT-1+ MPs demonstrated stronger correlations with Acute Physiology and Chronic Health Evaluation III scores, unassisted breathing, and multiple system organ failure. These findings warrant further exploration of the mechanistic role of TLT-1+ PMP in ARDS or acute lung injury progression.
- | pentoxifylline / Generic mfg.
Journal: Pentoxifylline as a therapeutic option for preeclampsia: a study on its placental effects. (Pubmed Central) - Oct 18, 2022
Its beneficial effects on the NO pathway and inflammation are not retained in pre-eclampsia, limiting its application in this disease, although it could be useful for other placenta-related disorders. Future studies might focus on selective A receptor antagonists as a new treatment for pre-eclampsia.
- | Lisofylline / Islet Sci
Journal: Interleukin-23 Mediates Osteoclastogenesis in Collagen-Induced Arthritis by Modulating MicroRNA-223. (Pubmed Central) - Sep 18, 2022
Lentiviral vectors expressing short hairpin RNA (shRNA) targeting IL-23p19 and lisofylline (LSF) were injected intraperitoneally into arthritic mice...This study is the first to demonstrate that IL-23 promotes osteoclastogenesis by transcriptional regulation of miR-223 in murine macrophages and mice with CIA. Furthermore, our data indicate that LSF, a selective inhibitor of STAT4, should be an ideal therapeutic agent for treating RA through down-regulating miR-223-associated osteoclastogenesis.
- | Lisofylline / Islet Sci
Preclinical, Journal: Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. (Pubmed Central) - Jan 19, 2022
We observed that LSF alleviated obesity-induced cardiac injury indirectly by improving both pancreatic β-cell function and insulin sensitivity, as well as, directly via upregulation of cardiac AMPK expression and downregulation of cardiac inflammation and apoptosis. LSF may represent an effective therapy targeting obesity-induced metabolic and cardiovascular complications.
- || Lisofylline / Islet Sci
Review, Journal: Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. (Pubmed Central) - Jan 8, 2022
Several pharmacological agents, including corticosteroids, nitric oxide, neuromuscular blocker, anti-TNF, statins, and exogenous surfactant, have been studied and some are under investigation, like ketoconazole, lisofylline, N-acetylcysteine, prostaglandins, prostacyclin, and fish oil. The purpose of this review is to appraise the understanding of the pathophysiology of ARDS, biomarkers, and clinical trials of pharmacological therapies of ARDS and COVID-19-related ARDS.
- | Lisofylline / Islet Sci
Journal: Role of Chain Length and Degree of Unsaturation of Fatty Acids in the Physicochemical and Pharmacological Behavior of Drug-Fatty Acid Conjugates in Diabetes. (Pubmed Central) - Dec 16, 2021
In the present study, four different FAs (linoleic acid, oleic acid, palmitic acid, and α-lipoic acid) were selected based on their chain length and degree of unsaturation and conjugated to Lisofylline (LSF), an antidiabetic molecule to obtain different drug-FA prodrugs and characterized for molecular weight, hydrophobicity, purity, self-assembly, and efficacy in vitro and in vivo in type 1 diabetes model...Diabetic animals treated with prodrugs, once daily for 5 weeks, maintained a steady fasting blood glucose level with a significant increase in insulin level, considerable restoration of biochemical parameters, and preserved β-cells integrity. Among the different LSF-FA prodrugs, LSF-OA and LSF-PA demonstrated the most favorable physicochemical, systemic pharmacokinetic, and pharmacodynamic profiles.
- || Lisofylline / Islet Sci
PK/PD data, Preclinical, Journal: Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat. (Pubmed Central) - Apr 27, 2021
Pharmacokinetic studies of LSF-LA PLM tablet showed greater C than LSF, LSF-LA, and LSF-LA PLM. Designed facile LSF-LA PLM tablet dosage form has potential for an immediate decrease in the postprandial glucose levels in patients of T1D.
- || Lisofylline / Islet Sciences
Clinical, Journal: A scalable self-assembling micellar system for enhanced oral bioavailability and efficacy of lisofylline for treatment of type-I diabetes. (Pubmed Central) - Jul 29, 2020
Production of inflammatory cytokines (TNF-α and IFN-γ) and different biochemical markers for liver and kidney functions were much reduced in diabetic animals after treatment with LSF-LA PLM. LSF-LA PLM treated pancreatic sections showed minimal infiltration of CD4+ and CD8+ T-cells as indicated by H&E staining and immunohistochemical analysis.
- || Lisofylline / Islet Sciences
PK/PD data, Preclinical, Journal: Comparative Assessment of the New PDE7 Inhibitor - GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach. (Pubmed Central) - Jan 4, 2020
GRMS-55 and (±)-LSF seem to be promising candidates for future studies on the treatment of immune-related diseases. The developed PK/PD models may be used to assess the anti-inflammatory and anti-arthritic potency of new compounds for the treatment of rheumatoid arthritis and other inflammatory disorders.
- || pentoxifylline / Generic mfg.
Clinical, Clinical data, PK/PD data, Journal: Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotising enterocolitis: a pilot study incorporating clinical outcomes. (Pubmed Central) - Jan 1, 2020
The developed PK/PD models may be used to assess the anti-inflammatory and anti-arthritic potency of new compounds for the treatment of rheumatoid arthritis and other inflammatory disorders. The developed model can be used to explore dosing strategies based on size and maturation for pre-term infants.
- || Lisofylline / Islet Sciences
PK/PD data, Preclinical, Journal: Influence of inflammatory disorders on pharmacokinetics of lisofylline in rats: implications for studies in humans. (Pubmed Central) - Dec 23, 2019
Too low LSF serum levels might have been one of the reasons for clinical trial failures. A long-term i.v. infusion of LSF seems to be more effective compared to short-term multiple infusions that were used in clinical trials, as it may provide concentrations above IC for inhibition of both TNF-alpha release and cAMP degradation in serum for a longer period of time.
- | Simdax (levosimendan IV) / AbbVie
Clinical, Review, Journal: Pharmacological agents for adults with acute respiratory distress syndrome. (Pubmed Central) - Sep 30, 2019
Three studies awaiting classification may alter the conclusions of this review. As the potential long-term consequences of ARDS are important to survivors, future research should incorporate a longer follow-up to measure the impacts on quality of life.
- Lisofylline / Islet Sci
Trial completion: Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 30, 2014
P1/2, N=8, Completed, Sponsor: DiaKine Therapeutics, Inc.
As the potential long-term consequences of ARDS are important to survivors, future research should incorporate a longer follow-up to measure the impacts on quality of life. Recruiting --> Completed
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Trial primary completion date: Strategies to Improve Islet Survival (clinicaltrials.gov) - Jun 19, 2014
P2, N=5, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Trial primary completion date: Aug 2013 --> Nov 2011
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Trial completion: Strategies to Improve Islet Survival (clinicaltrials.gov) - Jun 19, 2014
P2, N=5, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2013 --> Nov 2011 Active, not recruiting --> Completed
- Lisofylline / Islet Sci
Trial termination: Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 1, 2014
P1/2, N=1, Terminated, Sponsor: Eastern Virginia Medical School
Active, not recruiting --> Completed Recruiting --> Terminated; Unable to enroll sufficient number of subjects
- Lisofylline / Islet Sci
New P1/2 trial: Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 20, 2012
P1/2, N=1, Terminated, Sponsor: Eastern Virginia Medical School
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Enrollment change: Strategies to Improve Islet Survival (clinicaltrials.gov) - Jan 11, 2012
P2, N=5, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Terminated; Unable to enroll sufficient number of subjects N=24 --> 5
- Simulect (basiliximab) / Novartis, Lisofylline / Islet Sci
Enrollment closed: Strategies to Improve Islet Survival (clinicaltrials.gov) - Sep 25, 2011
P2, N=5, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=24 --> 5 Recruiting --> Active, not recruiting